About: Bio-Israel

Vaxil Bio has become the first Israeli biotech company to trade on the Toronto Stock Market. Vaxil’s shares are now trading under the symbol VXL. At a deemed value of $0.23 per share, the Company’s market value is approximately $11-Million. The Company’s financing and go-public were led by Sunel Securities Inc.</p> Vaxil...

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, today reported further progress in its continuing preclinical program of its CF602 drug candidate as the Company prepares to file an investigational new drug (IND) application...

Immune Pharmaceuticals Inc. (NASDAQ: IMNP) announced today that it has initiated its Phase II Ulcerative Colitis clinical trial and is scheduled to initiate its Phase II Bullous Pemphigoid clinical trial on July 1, 2015. Study Initiation is the training of hospital staff to allow for patient screening and immediate patient...

RedHill Biopharma announced positive top-line results from its Phase III study with RHB-105 for the treatment of Helicobacter pylori (H. pylori) bacterial infection. Top-line results from the study demonstrated 89.4% efficacy in eradicating H. pylori infection with RHB-105. The ERADICATE Hp first Phase III study successfully met its primary endpoint...

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), announced favorable data from further analysis of its Phase II/III double-blind, placebo-controlled study designed to test the efficacy of CF101 in patients with moderate-to-severe plaque psoriasis. The study included 326 patients through 17 clinical centers in the U.S., Europe, and Israel with...